Morgan Stanley’s ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) ECTE Stock Holding History

Morgan Stanley’s Portfolio ECTE Stock Details ECTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-801	Closed	-$1K	–	6716
2016 Q2	$1K	Sell	801 -15	-2%	-$24	﹤0.01%	6477
2016 Q1	$1K	Sell	816 -3	-0.4%	-$4	﹤0.01%	6523
2015 Q4	$1K	Buy	819 +19	+2%	+$31	﹤0.01%	6615
2015 Q3	$1K	Sell	800 -620	-44%	-$988	﹤0.01%	6569
2015 Q2	$2K	Sell	1,420 -4,380	-76%	-$7.32K	﹤0.01%	6537
2015 Q1	$12K	Sell	5,800 -1,758	-23%	-$4.12K	﹤0.01%	6196
2014 Q4	$10K	Sell	7,558 -1,165	-13%	-$1.01K	﹤0.01%	6225
2014 Q3	$8K	Sell	8,723 -6,138	-41%	-$11.1K	﹤0.01%	6256
2014 Q2	$34K	Sell	14,861 -598	-4%	-$1.49K	﹤0.01%	5887
2014 Q1	$47K	Buy	15,459 +3,680	+31%	+$12.1K	﹤0.01%	5739
2013 Q4	$36K	Sell	11,779 -3,658	-24%	-$10.2K	﹤0.01%	5720
2013 Q3	$43K	Buy	+15,437	New	+$41.8K	﹤0.01%	5213

Other funds holding ECTE

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Morgan Stanley's ECTE Position: Q3 2016 in Review

Morgan Stanley sold out of ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) (ECTE) in Q3 2016, closing a stake of 801 shares — an estimated $1K sold.

Morgan Stanley first reported a position in ECTE in Q3 2013 and held it in 12 quarters. The position peaked at $47K in Q1 2014. 2 funds tracked by Wall St. Rank hold ECTE as of Q3 2016.

Morgan Stanley reported no remaining ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position as of Q3 2016 after selling out during the quarter.
Morgan Stanley sold 801 ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) shares in Q3 2016, an estimated $1K.
Morgan Stanley first reported a position in ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) in Q3 2013 and held it in 12 quarters.
Morgan Stanley's ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position peaked at $47K in Q1 2014.
2 funds tracked by Wall St. Rank held ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) as of Q3 2016.

Based on Morgan Stanley's 13F filing for Q3 2016, filed 10 Nov 2016.